Last reviewed · How we verify
Unresectable or metastatic solid tumors with BRAF V600E mutation
Approved treatments
- Mekinist · Novartis
Mekinist works by blocking a specific enzyme called BRAF V600E, which is involved in the growth and spread of cancer cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Unresectable or metastatic solid tumors with BRAF V600E mutation patent landscape — cliff calendar, originator estates, attackable patents
- Unresectable or metastatic solid tumors with BRAF V600E mutation treatment landscape brief
- Unresectable or metastatic solid tumors with BRAF V600E mutation treatment updates RSS
Frequently asked questions about Unresectable or metastatic solid tumors with BRAF V600E mutation
What drugs treat Unresectable or metastatic solid tumors with BRAF V600E mutation?
Tracked treatments include Mekinist.
What is the treatment for Unresectable or metastatic solid tumors with BRAF V600E mutation?
Standard treatment for Unresectable or metastatic solid tumors with BRAF V600E mutation includes Mekinist. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Unresectable or metastatic solid tumors with BRAF V600E mutation patent cliff · Unresectable or metastatic solid tumors with BRAF V600E mutation CI report
- Treatment: Mekinist · Novartis
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing